China (Mainland)
4-(METHYLAMINO)-3-NITROBENZOIC ACID CAS NO.41263-74-5
- FOB Price: USD: 10.00-10.00 /Metric Ton Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: T/T,Other
- Available Specifications:
98%(1-10)Metric Ton
- Product Details
Keywords
- 4-(METHYLAMINO)-3-NITROBENZOIC ACID
- 41263-74-5
- high purity>99%
Quick Details
- ProName: 4-(METHYLAMINO)-3-NITROBENZOIC ACID
- CasNo: 41263-74-5
- Molecular Formula: 734.962
- Appearance: white powder
- Application: only for research
- DeliveryTime: 24hours
- PackAge: 1kg
- Port: SHANG HAI
- ProductionCapacity: 1000 Kilogram/Week
- Purity: 99.5%
- Storage: Dry preservation
- Transportation: sea ,air
- LimitNum: 1 Kilogram
- Moisture Content: 0.1%
- Impurity: 0.06%
Superiority
in stock
Assay:99% white powder
dentification(HPLC) ：The retention time of the major peak in the chromatogram of the assay preparation corresponds to that in the chromatogram of the Conformal standard preparation, as obtained in the assay
Single impurities ≤0.1%
Total impurities ≤0.4%
Wuhan Yingyuanbei Biotechnology Co., Ltd. is a high-tech enterprise specializing in R&D and production of pharmaceutical raw materials and intermediates.
At present, the company's research team is composed of dozens of high-tech personnel. At present, there is a great breakthrough in the research of raw materials for various cancers and complex diseases. It has been able to independently develop hundreds of pharmaceutical raw materials and intermediates, most of which have completed mass production.
Details
CBNumber: CB0441656
Bezeichnung: 4-(METHYLAMINO)-3-NITROBENZOIC ACID
Summenformel: C8H8N2O4
Molgewicht: 196.16
CAS-Nr.: 41263-74-5
MOL-Datei: MOL-Datei
Wuhan Yingyuanbei Biotechnology Co., Ltd. is a high-tech enterprise specializing in R&D and production of pharmaceutical raw materials and intermediates.
At present, the company's research team is composed of dozens of high-tech personnel. At present, there is a great breakthrough in the research of raw materials for various cancers and complex diseases. It has been able to independently develop hundreds of pharmaceutical raw materials and intermediates, most of which have completed mass production.